Inogen Business Summary

Inogen Inc. (INGN) is a medical technology leader specializing in portable oxygen concentrators (POCs) designed to provide mobility for patients with chronic respiratory conditions like COPD. The company operates a multi-channel revenue model consisting of direct-to-consumer (DTC) sales, business-to-business (B2B) distribution to domestic and international home medical equipment (HME) providers, and recurring rental income from its domestic patient fleet. Its primary business segments include DTC, Domestic B2B, International B2B—the latter being its largest segment as of early 2026—and Rental. Inogen’s product portfolio, featuring the Rove series and Voxi 5 stationary concentrator, competes directly with Drive DeVilbiss Healthcare, Invacare, Belluscura, and Philips Respironics. Inogen distinguishes itself as a premier branded player in the global POC market, utilizing a robust digital marketing engine and a strategic shift toward total-cost-of-ownership value propositions to maintain a competitive edge over traditional, HME-centric rivals. Founded in 2001 by Alison Bauerlein, Brenton Taylor, and Byron Myers, Inogen is currently led by President and CEO Kevin Smith, who brings over 20 years of medical device pedigree from Sirtex Medical and Teleflex. The leadership team includes CFO Michael Bourque, formerly of Chase Corporation, and CTO Naga Rameswamy, a digital health veteran from Alcon and GE Healthcare who joined in September 2025 to accelerate the company’s innovation pipeline. Other key executives include Chief Commercial Officer Gregoire Ramade and Chief Medical Officer Krishna Jhaveri. The company is governed by a board chaired by Elizabeth Mora and includes directors like Mira Sahney, a former Medtronic executive. Notable investors include institutional giants BlackRock and Vanguard, as well as Yuwell Medical, which maintains a strategic 9.9% stake to support Inogen’s expansion into the Chinese respiratory market.